Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalty ranging from a high-single digit to low-double digit percentage of worldwide net sales of frexalimab. As a result of today's announced transaction, Royalty Pharma will receive 100% of net royalties on annual worldwide net sales of frexalimab of up to $2.0 billion and share a minority of the royalties above this threshold with ImmuNext shareholders.
根据ImmunExt与赛诺菲签订的许可协议条款，Immunext有权获得向上分级的净特许权使用费，其占弗雷沙利单抗全球净销售额的百分比从高个位数到低两位数的百分比不等。根据今天宣布的交易，Royalty Pharma将获得不超过20亿美元的frexalimab全球年净销售额的100％净特许权使用费，并与ImmunExt股东分享超过该门槛的少数特许权使用费。
In addition, the acquisition will include substantial potential milestone payments from Sanofi. Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.
此外，此次收购还将包括来自赛诺菲的大量潜在里程碑付款。Royalty Pharma估计，如果获得批准，弗雷沙利单抗将在2041年之前产生特许权使用费。
Frexalimab, in development by Sanofi, is a first-in-class, second generation anti-CD40 ligand monoclonal antibody.
Frexalimab由赛诺菲开发，是同类首创的第二代抗CD40配体单克隆抗体。
译文内容由第三方软件翻译。